miR-210 diminishes the cellular rigidity of colorectal cancer stem cells (CRCSCs) by targeting Stathmin1 (STMN1), thereby enhancing their invasiveness, a process that is independent of epithelial–mesenchymal transition (EMT). The gene discussed is STMN1; the disease is colorectal cancer.